Trajenta Duo Tablet 2.5/850 mg

Adult dose

This medication is administered twice daily with meals. To reduce gastrointestinal side effects related to metformin use, dosage increases should be gradual. 1. If currently not treated with metformin: Take this medication 2.5/500 mg twice daily, 1 tablet each time, with the possibility to increase to 2.5/1000 mg up to twice daily, 1 tablet each time. 2. If sufficient blood sugar control is not achieved with metformin monotherapy.

This medication may rarely cause a serious side effect known as lactic acidosis due to one of its active ingredients, metformin hydrochloride. The risk of lactic acidosis increases in patients with impaired kidney function, or issues with heart or liver function, so those with such conditions should not take this medication. Additionally, this medication should not be administered to individuals with hypersensitivity to it, type 1 diabetes, diabetic ketoacidosis, severe kidney impairment, acute myocardial infarction, liver dysfunction, acute alcohol intoxication, women who are pregnant or breastfeeding. The dosage of this medication needs to be adjusted according to kidney function, and it should not be taken in cases of severe renal impairment. It is crucial to regularly check kidney function before and during treatment. Caution is advised when taken alongside sulfonylureas or insulin as there is a risk of hypoglycemia, and dosage adjustments may be necessary. During treatment with this medication, rare skin disorders such as acute pancreatitis or bullous pemphigoid may occur; hence, patients should promptly inform healthcare providers if severe abdominal pain or skin blisters appear. Long-term use may result in vitamin B12 deficiency, so if anemia or neurological symptoms develop, blood tests should be conducted to check vitamin B12 levels. This medication increases the risk of lactic acidosis when taken with alcohol, so alcohol consumption should be avoided. If iodinated contrast media is used during radiological examinations, there is a risk of impaired kidney function, therefore this medication should be stopped for a certain period before and after the examination, and kidney function reassessed. Elderly patients are at a higher risk of reduced kidney function, so dosage should be carefully adjusted and kidney function routinely monitored. Women who are pregnant or planning to become pregnant should avoid this medication, and it is also advised not to take it while breastfeeding. This medication is not recommended for children under 10 years old, and the safety and effectiveness in pediatric patients over 10 have not been sufficiently established. In cases of overdose, there is a risk of lactic acidosis, so immediate hospital treatment should be sought, and if necessary, the drug can be eliminated by hemodialysis. This medication should be kept out of the reach of children, stored in a dry place, and not transferred to another container. Finally, patients with or suspected of having mitochondrial disease should not use this medication, and if symptoms appear, treatment should be immediately discontinued, and a diagnosis should be sought.

Serious side effects

Urticaria, angioedema, lactic acidosis, pancreatitis, bullous pemphigoid, liver function abnormalities (including liver function test abnormalities and hepatitis), acute myocardial infarction, heart failure, cardiac arrest, unstable angina, angina, acute kidney injury, end-stage renal disease, pneumonia, asthma, dyspnea, respiratory issues, facial swelling, severe edema, severe cases of hypoglycemia, acute pancreatitis, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, acute pyelonephritis, sepsis,

Mild side effects

• Hypoglycemia
• taste disorder
• cough
• decreased appetite
• diarrhea
• constipation
• nausea
• pancreatitis
• vomiting
• abdominal pain

This medication must be kept in a tightly sealed container to prevent exposure to air and moisture. Additionally, it is advisable to avoid storage in excessively hot or cold places and keep it at normal room temperature between 1°C and 30°C.

Appearance

Biconvex oval film-coated tablet in bright orange color

Package unit

60 tablets/box [(10 tablets/PTP packaging x 6)]